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Background. Chinese medicine (CM) has been used to relieve symptoms relevant to uterine fibroids. Objective. This study
investigated the association between the use of CM and the incidence of uterine surgery in women with uterine fibroids. Subjects
and Methods. This retrospective cohort study extracted records for 16,690 subjects diagnosed with a uterine fibroid between 2000
and 2003 from the National Health Insurance reimbursement database. The risk factors for surgery were examined via Cox
proportional hazard analysis, and the difference in incidence of surgery between CM users and nonusers was compared using
incidence rate ratios (IRRs) derived from Poisson’s models. Results. After an average follow-up period of 4.5 years, the cumulative
incidence of uterine surgery was significantly lower in CM users than CM nonusers (P < 0.0001). Compared to CM nonusers,
CM users were more unlikely to undergo uterine surgery (adjusted hazard ratio = 0.18, 95% confidence interval (CI)= 0.17, 0.19).
The incidence of surgery in CM users was dramatically different from that for CM nonusers (IRR= 0.17, 95% CI= 0.16, 0.18).
Conclusion. The risk of uterine surgery among fibroid patients who used CM was significantly decreased, implying an effective
treatment of fibroid-related symptoms provided by CM.
1. Introduction
Uterine fibroids, also known as leiomyoma, are the most
commonly occurring benign tumors of the female repro-
ductive system, with a cumulative incidence of more than
60% in women over the age of 45 years [1]. They are the
leading indication for hysterectomy all over the world and are
associated with a substantial economic impact on health care
systems, including associated costs of $4–9 billion per year
in the United States alone [2]. These tumors grow frequently
in women of reproductive age, regressing after menopause
[3], and can cause various symptoms including infertility,
pregnancy complications [4], pelvic pain [5], and abnormal
or heavy bleeding that can lead to anemia [6].
Surgery has traditionally been the gold standard for the
treatment of symptomatic uterine fibroids. Hysterectomy
is indicated in women who have completed childbearing,
particularly in those who are expected to go into menopause
soon, while myomectomy is indicated in women who wish
to preserve their fertility [7]. For asymptomatic patients,
on the other hand, serial followups (without surgery)
to monitor the size of the tumor and check for related
symptoms are advisable [8]. Surgery is an invasive treatment
that can cause even more severe complications than a
fibroid itself. Potential short-term complications of surgery
include febrile morbidity, blood loss, and organ injuries
[9], while possible long-term complications, such as fistula
formation, adhesion, and sexual dysfunctions [10], can
last for many years, even beyond menopause, when a
uterine leiomyoma is no longer a threat to health [3].
Consequently, alternative treatments to surgery for the
management of fibroid-related symptoms have been sought
and evaluated for years to minimize surgery in patients
[11].
2 Evidence-Based Complementary and Alternative Medicine
In Asian countries, Chinese medicine (CM) is one of the
most commonly used complementary alternative medicines
and has been reported to be used more by females than by
males around the world [12–16]. In Taiwan, CM has been
covered by the National Health Insurance (NHI) system since
1995 [17, 18]. According to the NHI database, diseases of
the female reproductive system, including menstruation dis-
orders, abnormal bleeding, and noninflammatory disorders
of female genital organs, are on the list of the top twenty
most common diseases for which patients utilize CM [19].
The high utilization rate of CM for these symptoms, all of
which are potentially related to uterine fibroids, implies the
possibility that CMmight treat those symptoms and, in turn,
reduce surgery among patients with uterine fibroids.
This population-based retrospective cohort study used
a national insurance reimbursement database to investigate
the association between the use of CM and the incidence of
uterine surgery in women with uterine fibroids. The results
provide population-based evidence for the benefit of CM in
women with uterine fibroids.
2. Materials and Methods
2.1. Study Subjects. This study used the Longitudinal Health
Insurance Database 2000 (LHID2000), which is a part
of the National Health Insurance Research Database set
up by Taiwan’s National Health Research Institutes. This
database contains chronological information on one million
randomly selected individuals who were beneficiaries from
1996 to 2000. There are no differences in gender and
age between the beneficiaries in the LHID2000 and the
beneficiaries in the entire NHI database. The beneficiary
information includes gender, birth date, income, occupation
status, area of registration, all medical claims for inpatient
and outpatient care, the dates of visits, and up to three diag-
nostic codes in the International Classification of Diseases,
9th Revision, Clinical Modification (ICD-9-CM) of these
beneficiaries from 1996 to 2009.
A total of 16,848 women were diagnosed with uterine
fibroid (ICD-9-CM 218) from 2000 to 2003 in outpatient
visits. The diagnosis date was used as the entry date and
surgery was defined as the outcome. There were 158 women
who were excluded because they had undergone uterine
surgery before the entry date. The remaining 16,690 women
were selected as research subjects and divided into CM users
and CMnonusers according to their use (or nonuse) of orally
administered CM between the entry date and endpoint date.
The endpoint date was defined as the date of surgery, death,
withdrawal from the insurance program, or December 31,
2009.
The examined variables were sociodemographic fac-
tors, including age (<20, 20–29, 30–39, 40–49, and ≥50
years), income level (<564.3, 564.3–656.5, 656.6–779.6,
and ≥779.7 US$ per month based on quartile), occu-
pation status (white collar, blue collar, and others), and
registered location (northern, central, southern, eastern,
and island), and fibroid-related comorbidities, including
excessive menstruation (ICD-9-CM 626.2), iron-deficiency
anemia (ICD-9-CM280), dysmenorrhea (ICD-9-CM625.3),
and infertility (ICD-9-CM 628 and 628.3).
2.2. Statistical Analysis. The chi-square test and t-test were
used to assess differences for categorical and continuous
variables between CM users and CM nonusers, respectively.
Cox proportional regression was used to estimate the hazard
ratio (HR) and its 95% confidence intervals (CIs) for
undergoing surgery. The Kaplan-Meier method was used
to plot the cumulative incidence, and the log-rank test was
used to test the difference in cumulative rates between CM
users and nonusers. Adjusted models were controlled for age,
occupation, area, excessive menstruation, iron-deficiency
anemia, and dysmenorrhea. The incidence rate (IR) for
surgery (per 1000 person-years) was also calculated. The
association between the use of CM and uterine surgery
was estimated by using the incidence rate ratio (IRR)
and the corresponding 95% CI by Poissons distribution
model. All statistical analyses were performed using SAS
software, version 9.1 (SAS Institute Inc., Carey, NC), and the
significance level was set at a two-tailed P value of less than
0.05.
3. Results
3.1. Characteristics of CM Users and CM Nonusers in Fibroid
Patients. Among the 16,690 females with a uterine fibroid
diagnosis from 2000 to 2003, 12,238 (73.3%) used CM
between the diagnosis and endpoint date. The mean age of
CM users (41.6 years) was lower than that of CM nonusers
(42.9 years). Significantly, the proportion of patients among
CM users who were young (under 40), white collar, and
registered their insurance in Central Taiwan was higher than
that among CM nonusers. In terms of comorbidity, CM
users were more likely to have fibroid-related comorbidities,
including excessive menstruation, anemia, and dysmenor-
rhea (Table 1).
3.2. Risk Factors for Uterine Surgery among Fibroid Patients.
At the end of the observation, 22% of the patients (n =
3681) received surgery of the uterus, including myomec-
tomy and hysterectomy. Compared to nonusers, CM users
were significantly more unlikely to undergo surgery after
adjustment for socio-demographic factors (age, occupation,
and area) and comorbid covariates (excessive menstruation,
iron-deficiency anemia, and dysmenorrhea), with an HR of
0.18 (Table 2). The adjusted HRs for surgery were more
than double among patients between 30 and 50 years of age
compared to those who were under 30 years old. Adjusted
HRs were also higher among patients who were blue collar,
registered in Central and Southern Taiwan, and whose
diseases were comorbid with excessive menstruation, iron-
deficiency anemia, and dysmenorrhea. The mean observa-
tion time in this cohort was 4.5 years.
3.3. Incidence of Surgery among CM Users and CM Nonusers.
At the end of observation, 8.7% of CM users and 46.6%
of CM nonusers have undergone surgery. Kaplan-Meier’s
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Table 1: Comparison of socio-demographic factors and co-morbidities between Chinese medicine (CM) users and nonusers in patients
with uterine fibroids.
CM Nonusers
N = 4452
CM Users
N = 12238
Total
N = 16690 P value
a
n % n % n %
Age, years <0.0001
<20 18 0.40 110 0.90 128 0.77
20–29 268 6.02 1151 9.41 1419 8.50
30–39 1120 25.2 3603 29.4 4723 28.3
40–49 2394 53.8 5643 46.1 8037 48.2
≥50 652 14.7 1731 14.1 2383 14.3
Mean ± SD 42.9 ± 8.20 41.6 ± 8.84 41.9 ± 8.69 <0.0001
Income, US$ per month 0.86
<564.3 1178 26.5 3276 26.8 4454 26.7
564.3–656.5 868 19.5 2438 19.9 3306 19.8
656.6–779.6 1293 29.0 3514 28.7 4807 28.8
≥779.7 1113 25.0 3010 24.6 4123 24.7
Occupational status 0.009
White collar 2454 55.1 7015 57.3 9469 56.8
Blue collar 1500 33.7 4016 32.8 5516 33.1
Others 498 11.2 1202 9.83 1700 10.2
Area <0.0001
Northern Taiwan 2288 51.4 5505 45.0 7793 46.7
Central Taiwan 604 13.6 2353 19.2 2957 17.7
Southern Taiwan 1364 30.6 3852 31.5 5216 31.3
Eastern Taiwan and offshore islands 196 4.40 523 4.28 719 4.31
Comorbidity
Excessive menstruation 782 17.6 2718 22.2 3500 21.0 <0.0001
Iron-deficiency anemia 473 10.6 1549 12.7 2022 12.1 0.0004
Dysmenorrhea 555 12.5 2571 21.0 3126 18.7 <0.0001
Infertility 9 0.20 94 0.77 103 0.62 <0.0001
a
Chi-square test and t-test.
analysis showed a significant difference in cumulative inci-
dence of surgery between CM users and nonusers (P <
0.0001, Figure 1). This difference developed rapidly in the
first several months after the diagnosis of a uterine fibroid.
The overall IR for surgery among CM users was 17.7
per 1,000 fibroid patients, while that among CM nonusers
was 103.7 per 1,000. Poisson’s regression modeling revealed
that the IRs for surgery were lower among CM users in all
demographic subgroups except for those younger than 20
years of age. In terms of fibroid-related comorbidity, the
IRs were also lower for CM users than for CM nonusers
whether patients had excessive menstruation, anemia, and
dysmenorrhea or not, while the IRs were similar between CM
users and nonusers among patients with infertility (Table 3).
In light of the rapid development of the difference
in the cumulative incidence of surgery between the two
groups, time lag stratification was performed to rule out the
possibility that rapid decisions in favor of surgery biased the
results (Table 4). Adjusted HRs for surgery remained lower
in CM users than in CM nonusers even after the deletion of
subjects with a diagnosis-to-surgery period of less than three
months to five years, but the adjusted HR for surgery in CM
users increased from 0.33 to 0.79 compared to nonusers.
4. Discussion
This retrospective cohort study investigated the relationship
between the use of CM and the incidence of uterine surgery
in women with uterine fibroids using an NHI database
documenting medical claims from 1996 to 2009. After
an average follow-up time of 4.5 years, the data shows
that patients who received CM had a significantly lower
risk of uterine surgery compared to patients who did not
receive CM treatment. Moreover, the incidence of surgery
in CM nonusers was more than five times higher than in
CM users. The low surgery incidence in CM users was
not affected by age, income, occupational status, area of
insurance registration, or comorbidities including excessive
menstruation, iron-deficiency anemia, and dysmenorrhea.
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Table 2: Crude/adjusted hazard ratios and 95% confidence intervals for undergoing surgery.
Crude Adjusteda
HR (95% CI) HR (95% CI)
CM
No 1.00 (Reference) 1.00 (Reference)
Yes 0.20 (0.18–0.21)∗∗∗ 0.18 (0.17–0.19)∗∗∗
Age, years
<30 1.00 (Reference) 1.00 (Reference)
30–39 2.65 (2.24–3.14)∗∗∗ 2.36 (1.99–2.80)∗∗∗
40–49 3.00 (2.54–3.54)∗∗∗ 2.54 (2.15–3.00)∗∗∗
≥50 1.35 (1.11–1.64)∗∗ 1.24 (1.02–1.51)∗
Occupational status
White collar 1.00 (Reference) 1.00 (Reference)
Blue collar 1.18 (1.11–1.27)∗∗∗ 1.15 (1.07–1.23)∗∗∗
Others 0.99 (0.89–1.11) 0.90 (0.81–1.01)
Area
Northern Taiwan 1.00 (Reference) 1.00 (Reference)
Central Taiwan 1.25 (1.15–1.37)∗∗∗ 1.51 (1.38–1.65)∗∗∗
Southern Taiwan 1.20 (1.12–1.30)∗∗∗ 1.26 (1.17–1.36)∗∗∗
Eastern Taiwan and offshore islands 1.09 (0.93–1.29) 1.03 (0.87–1.22)
Co-morbidity (versus no)
Excessive menstruation 1.34 (1.25–1.44)∗∗∗ 1.26 (1.17–1.36)∗∗∗
Iron-deficiency anemia 1.61 (1.48–1.75)∗∗∗ 1.56 (1.43–1.70)∗∗∗
Dysmenorrhea 1.23 (1.14–1.32)∗∗∗ 1.35 (1.25–1.47)∗∗∗
Infertility 0.68 (0.12–1.09) —
a
Adjusted for age, occupation, area, excessive menstruation, iron-deficiency anemia, and dysmenorrhea.
∗∗P < 0.01 and ∗∗∗P < 0.0001.
Time (year)
1086420
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0
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log-rank test, P < 0.0001
Figure 1: Kaplan-Meier analysis for cumulative incidence of uterine
surgery between CM users and CM nonusers.
The strength of the present study is that the database
we used was from the NHI, which is a government-run,
single-payer national health insurance program that insures
over 97% of citizens and over 99% of health-care institutes
[20, 21]; this rendered the present study representative of the
general population, thereby offering a comprehensive picture
of the risks of surgery in fibroid patients. The data revealed
a lower surgery incidence in fibroid patients who used CM
compared to those who did not use CM, implying that
Taiwanese women with uterine fibroids benefited sufficiently
from CM to avoid surgery. This study further suggested that
CM might provide an effective alternative therapy to surgery
for uterine fibroids.
Several studies have reported sociodemographic trends
regarding the use of CM in women. CM users have been
reported to be younger than CM nonusers when it comes
to women with constipation [22], insomnia [23], and
breast cancer [24], although the primary age group varies
from disease to disease. The present study supported such
findings by showing that patients under 40 with uterine
fibroids were more likely to use CM. In terms of income,
education, and occupational status, studies that have inves-
tigated female-specific diseases, including breast cancer and
gynecological malignancies, have reported that users of CM
and complementary medicines tend to be highly educated,
have high incomes, and are more likely to be employed
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by the government, schools, enterprises, and institutions
[24, 25]. The data of the present study, meanwhile, showed
that while CM users tended to be white collar instead of blue
collar workers, there were no differences in income between
CM users and nonusers. The present study also found that
there was a higher proportion of patients who registered
their insurance in Central Taiwan among CM users than
among CM nonusers, a finding being attributed to the high
density of Chinese medical institutes per person in Central
Taiwan [12, 24]. When taking into account comorbidities,
it appeared that fibroid patients with relevant comorbidities
tended to use CM. Since suffering from disease is one of
the factors that has been reported to positively and directly
influence the purchasing behavior of CM outpatients [26],
the existence of symptoms related to uterine fibroids might
be one of the factors that drove patients to utilize CM.
Analysis of the risk factors for surgery revealed that
patients who are more than 30 years of age, blue collar,
and registered in the Central and Southern regions were
more likely to undergo surgery. Moreover, fibroid-related
symptoms, including excessive menstruation, anemia, and
dysmenorrhea, were also risk factors for surgery (although
infertility was not related to surgery). These risk factors had
HRs ranging from 1.24 to 2.54. On the other hand, the
adjusted HR for surgery in CM users was 0.18 compared
to nonusers, indicating that CM nonusers were 5.5 times
more at risk of surgery than CM users. Moreover, the overall
IR of surgery for CM users was 0.17 times that of CM
nonusers. Both results imply that the use of CM was a
protective factor against surgery in fibroid patients. In the
stratified analysis, the IRRs of surgery in CM users for all
the subgroups of sociodemographic status and for almost
all the subgroups of comorbidities were lower than 0.25,
implying that the protective effect of CM was strong enough
to protect almost all the subgroups for sociodemographic
and comorbid status. Only in patients with infertility did
the difference in IR between CM users and nonusers not
exist. The reason was speculated to be that hysterectomy
is contraindicated for women who want to preserve their
fertility, and therefore patients with infertility did not tend
to receive surgery regardless of whether they utilized CM or
not.
Although there was a big difference in the cumulative
incidence of surgery between CM users and nonusers,
Kaplan-Meier’s analysis indicated that the difference
increased rapidly in the first few months after diagnosis.
Results for a time lag stratification revealed that even after
the deletion of subjects with a diagnosis-to-surgery period
of less than three months to five years, the differences in
IR between the two groups still existed, indicating that
there were still protective effects from CM in patients who
had been diagnosed for five years. However, the adjusted
HR for surgery increased from 0.33 to 0.79 with time lag
periods from three months to five years, indicating that
the protective effects were weakened in patients who had a
long diagnosis-to-surgery duration. We speculate that the
increased proportion of asymptomatic patients in groups of
long diagnosis-to-surgery duration caused the weakening of
CM protection. Surgery is not indicated in asymptomatic
patients; therefore, those who were asymptomatic would
not undergo surgery whether they took CM treatment or
not.
Clinical trials regarding the effects of CM on the outcome
of uterine fibroids are very limited. A small randomized
controlled trial with 25 women in total, using strict random-
ization methods and data management, showed that fibroids
shrank after treatment with a medicinal formulation of Nona
Roguy for six months; the shrinkage of fibroids for the CM
group was comparable to that in a mifepristone group [27].
Another trial with 25 subjects published in Japan showed that
one CM formula, Toki-shakuyaku-san, improved symptoms
of hypermenorrhea, dysmenorrhea, and anemia [28]. The
same group of researchers has also reported that CM elevates
hemoglobin levels in patients with iron-deficiency anemia
[29]. Other studies that show the effectiveness of CM
on uterine fibroids are either of low quality or contain
methodological flaws, such as a lack of randomization, not
being blind, or using improper data management [30]. The
present study provided epidemiological evidence showing
different outcomes between CM users and nonusers among
fibroid patients. This study elucidated the possible effect of
CM on uterine fibroids from the point of view of public
health, expressing the same idea with the above-mentioned
clinical studies.
As the database used by this study was produced
primarily for administrative and insurance claim purposes
and not for research, the first limitation of this study included
the possibility of errors in register information. Secondly, it
is also possible that there might have been slight differences
in the principle of treatment between hospitals. This might
account for the difference in the risk of surgery and CM
usage among different areas. Thirdly, the NHI does not cover
infertility, meaning that most infertility patients were not
registered in the NHI database, leading to possible bias in
our data related to infertility. Lastly, the most important
disadvantage of studies which extract data from the NHI
database is that the causal relationship cannot be clarified.
The negative correlation between surgery and the use of
CM could come from the effect of CM or the original
rejection of surgery by CMusers. Therefore, further rigorous,
randomized, multicentered, and double-blinded placebo-
controlled clinical trial should be carried out to study the
efficacy of CM.
5. Conclusion
The present study revealed that the risk and the incidence of
uterine surgery were lower in CM users than CM nonusers
among patients with uterine fibroids, implying an effective
treatment of fibroid-related symptoms provided by CM. The
low incidence of surgery in CM users existed in almost
all investigated sociodemographic and comorbid subgroups.
Further large clinical trials are obviously required to evaluate
the dimension of benefits that CM could provide. If the
protective effect described herein is confirmed, CM is worthy
of adoption by womenwith uterine fibroids not only in Asian
but also in Western countries.
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